A growth-focused global business executive, David has driven the industrialisation of Cell, Gene and Tissue therapies for almost 20 years. His performance track record across North America, Central Europe and Asia-Pacific includes supporting the manufacturing establishment of many of today’s commercial Cell Therapies.

David previously managed a global Cell Therapy automation business, leading a global team delivering commercial-scale manufacturing automation for the world’s leading biotherapeutics multinationals, developing bespoke manufacturing systems for emerging novel biotherapeutics at pre-clinical and early-clinical phases, and producing platform technologies for pioneering technology start-ups across the Cell Therapy landscape.

Initially a deeply technical engineer and scientist, David brings multi-sector leadership experience, including a period as a management consultant across industries as diverse as health, finance and primary industries, and has worked for and within businesses from Fortune 500s through start-ups. He focuses on establishing robust strategic, financial and operational foundations, from which to build powerful collaborations and drive meaningful change.

Defined by his fastidious attention to engineering detail, Mark has pushed the boundaries of new product development for almost 20 years. Teams under his guidance have twice been awarded Australia’s prestigious Good Design Award for biotech manufacturing systems. Mark brings a track record of success in evolving conceptual designs into quality manufacturable products within highly regulated environments.

Mark operated a project management office covering design and contract manufacture of life-science diagnostic and point-of-care devices, and previously spent 10 years developing next-generation Cell Therapy manufacturing systems for clients across the world, from large-scale allogeneic installations to point-of-care autologous manufacture. Mark’s pursuit of manufacturing excellence was forged in the automotive industry, managing future product design for advanced drivetrain systems including hybrid electric vehicles. He also established and operated a successful business in the automotive sector over a10-year growth trajectory.

Finessing the human experience is core to Mark’s approach, enabling his deep knowledge of complex engineering tools, techniques and systems to coalesce into automation systems of sophisticated simplicity. Mark brings a passion for leveraging great design to positively impact patient access to Cell Therapies.